Miguel Cordon · · 1 min readMalaysian biotech firm banks $5.7m in series A round
Biogenes Technologies develops, produces, and markets synthetic antibody diagnostics products via its proprietary platform. The biotech firm is headquartered in Malaysia and plans to enter Indonesia and the Philippines this year.
Funding details
- Funding amount: $5,700,000
- Other investor: Pembangunan Ekuiti
- Stage: Series A
- Source
More details
Biogenes Technologies→
|
||
| Stage | Amount (US$) | Investors |
| Seed | Undisclosed | Antler |
| Series A | $5.7M | Pembangunan Ekuiti Sdn Bhd |
| Total | $5.7M | |
See also: Series SEA: Who’s investing in the region’s biotech startups?
Editing by Samreen Ahmad and Lorenzo Kyle Subido
(And yes, we’re serious about ethics and transparency. More information here.)
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.
